Fig. 1. Targeting fusion proteins explored in this work incorporate the Siderocalin (Scn) mammalian protein, which recognizes negatively charged M(iii)-HOPO complexes (left, non-targeting control), and is fused either to an antibody fragment (Fab, middle) or trastuzumab (IgG, right).